Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Bivatuzumab

Generic Name: Bivatuzumab

Drug Type: Biotech

Unique Ingredient Identifier: 0A0Z1IJN86

Overview

Bivatuzumab (previously BIWA 4) is a humanized monoclonal antibody against CD44 v6.

Background

Bivatuzumab (previously BIWA 4) is a humanized monoclonal antibody against CD44 v6.

Indication

Investigated for use/treatment in cancer/tumors (unspecified) and head and neck cancer.

Associated Conditions

No associated conditions information available.

Clinical Trials

Single Dose Escalation Study of Bivatuzumab Mertansine in Female Patients With CD44v6 Positive Metastatic Breast Cancer

Phase 1

Completed

Posted: 2014/10/01

Sponsor:Boehringer Ingelheim

ID:NCT02254005

Dose Escalation of Bivatuzumab Mertansine in Female Patients With CD44v6 Positive Recurrent or Metastatic Breast Cancer

Phase 1

Terminated

Posted: 2014/10/01

Sponsor:Boehringer Ingelheim

ID:NCT02254031

Single Dose Escalation Study of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck

Phase 1

Completed

Posted: 2014/10/01

Sponsor:Boehringer Ingelheim

ID:NCT02254018

Dose Escalation of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck or Esophagus

Phase 1

Terminated

Posted: 2014/10/01

Sponsor:Boehringer Ingelheim

ID:NCT02254044

Biodistribution Study With 186 Re-labelled Humanised Monoclonal Antibody BIWA 4 in Patients With Adenocarcinoma of the Breast

Phase 1

Completed

Posted: 2014/07/30

Sponsor:Boehringer Ingelheim

ID:NCT02204046

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

No news found

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy